Our division conducts cutting-edge basic, translational and clinical research designed to improve understanding and predicting therapeutic drug responses. We specifically focus on genetics and nongenetic mechanisms of interindividual variability in drug effects. Our research projects encompass a broad range of areas including Cardiology, Nephrology, Obstetrics, Reproductive Endocrinology, Hematology/Oncology, Medical Oncology, GI/Hepatology and infectious diseases. Our ultimate goal is to personalize drug therapy by optimizing beneficial effects, while minimizing adverse effects and cost.
The Third Annual Indiana Clinical and Translational Sciences Institute (CTSI) Symposium on Disease and Therapeutic Response Modeling
Date: November 5 and 6, 2013
Download event flyer
David Haas named Editor at Prestigious Healthcare Review Group
David Haas, M.D, associate professor of obstetrics and gynecology and medicine at the Indiana University School of Medicine, named Editor at prestigious healthcare review group. Read more by clicking here.
Lang Li Joins CPT:PSP as an Associate Editor
The editorial leadership of CPT:PSP is pleased to announce that Lang Li, PhD, has joined the journal's editorial team.
Clinical Pharmacology is accepting applications from all areas of translational research. Applications in the areas of OB/GYN, Pediatrics and Geriatrics are especially encouraged. Click here for more information
Senior Research Professor:
The Division seeks applicants for the position of Assistant, Associate and Senior Research Professor within the Division of Clinical Pharmacology. Read more...
The Division of Clinical Pharmacology at the Indiana University School of Medicine seeks an outstanding scientist and clinician to join our world class team of scientists, clinicians and educators. Read more...
Recipients of $10,000 Challenge Announced !!
In July 2013, Clinical Pharmacology received a $10,000 donation from Robert and Sue Elgar. Dr. and Mrs. Elgar chose to donate this money because “we are really hoping to bring more attention to the issues with adverse drug reactions and are hoping more physicians will take part in donating funds for research in this area”. Read more...
The editorial leadership of CPT:PSP is pleased to announce that Lang Li, PhD, has joined the journal's editorial team. Dr. Li is an Associate Professor in the Department of Medical and Molecular Genetics in the Indiana University School of Medicine (IUSM). He is also the Interim Director of the Center for Computational Biology and Bioinformatics in the IUSM, and the Associate Director of the Indiana Institute of Personalized Medicine (IIPM). His expertise in using informatics, genomics, and statistics to investigate drug efficacy and safety problems is an outstanding addition to the editorial leadership of the journal, and we look forward to working with him.
David Haas, M.D, associate professor of obstetrics and gynecology and medicine at the Indiana University School of Medicine, has been promoted to the position of Editor at the Cochrane Collaboration's Pregnancy and Childbirth Group, the oldest and the busiest of the Cochrane Review Groups.
Read more by clicking here.
Research by Drs. Rolf Kreutz and David Flockhart is changing the way medications are prescribed.
Take a look in your medicine cabinet. How much do you know about the medications inside? In fact, how much does anyone really know about how the pills we ingest wend their way through our bodies and work their wonders? Not enough, it turns out. But a team of physicians and scientists at the Indiana University School of Medicine is taking a leading role in discovering more about how some commonly used drugs work and how an individual's genes affect the response. Full Article
Jamie Renbarger, M.D., has made two new discoveries with a drug that was approved in 1963, opening the door to new knowledge that may further help children with cancer. Renbarger knew that vincristine -- which is widely used to treat cancers in children – led to side effects that varied considerably between patients. But why? In the lab, she discovered that two enzymes, CYP3A5 and CYP3A4, metabolize vincristine differently. CYP3A5, which is found in approximately 70 percent of African-Americans and 10 percent to 20 percent of Caucasians, metabolizes vincristine much more efficiently than CYP3A4. Knowing which enzymes to target, Renbarger next compared toxicity in Caucasians with African Americans who had Acute Lymphoblastic Leukemia. She showed that Caucasians developed side effects – such as jaw pain, loss of reflexes, and constipation -- with vincristine more often than African-Americans possibly due to the fact that the CYP3A5 enzyme is found in fewer Caucasians. Currently, Renbarger is enrolling 140 children with preB acute lymphoblastic leukemia to determine the optimal dosing of vincristine for pediatric patients, which may improve survival for young cancer patients. Renbarger's studies tie into the Best Pharmaceuticals for Children Act (BPCA), which established a process for studying drugs used in children with the goal of improving pediatric therapeutics. Vincristine has been identified as a priority drug to study. Because of the ongoing studies at the IU Simon Cancer Center, Renbarger and her team are generating data unlike any other research currently underway.